Loading
An American laboratory company that sells gene-activity tests estimating how likely skin and eye cancers are to spread.
Castle Biosciences makes tissue tests that measure the activity of a fixed set of genes by reverse-transcription PCR and report a risk class: DecisionDx-Melanoma (31 genes) for stage I to III skin melanoma, DecisionDx-UM (15 transcripts) for uveal melanoma, and DecisionDx-SCC (40 genes) for cutaneous squamous cell carcinoma. Medicare's MolDX programme covers the melanoma and uveal melanoma classes of test under local coverage determinations L37725 and L37033, and lists molecular risk tests for cutaneous squamous cell carcinoma as not covered (L39583).
A tissue test for stage I to III skin melanoma that measures 31 genes to estimate the chance of the melanoma spreading.
A test on a small sample of an eye melanoma that measures 15 transcripts to estimate how likely it is to spread, often to the liver.
A tissue test for high-risk squamous cell skin cancer that measures 40 genes to estimate the chance of spread; Medicare does not cover it.
Shares DecisionDx-UM, Gene-expression prognostic assays, Uveal melanoma.
Shares DecisionDx-SCC, Gene-expression prognostic assays, Cutaneous squamous cell carcinoma.
Shares DecisionDx-Melanoma, Gene-expression prognostic assays, Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/